Replies to post #45339 on Ayala Pharmaceuticals Inc (ADXS)

[gbrown6332]

I’ll interject in response to your question.

Dr. Petit indicated during the initial presentation on ADXS biomarker research mid-year, they had applied new biomarker criteria to the AXAL test group data that produced OS percentages of 38%. OS jumped to 50% for those patients who had favorable biomarker profiles after the data was re-evaluated.

Meaningful, but hasn’t gotten much press.

G.B.